Evogene Ltd. - Ordinary Shares (EVGN) News
Filter EVGN News Items
EVGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVGN News Highlights
- For EVGN, its 30 day story count is now at 4.
- Over the past 16 days, the trend for EVGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about EVGN are BIO, AG and CGEN.
Latest EVGN News From Around the Web
Below are the latest news stories about EVOGENE LTD that investors may wish to consider to help them evaluate EVGN as an investment opportunity.
Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), is gearing up for participation in the JP Morgan 42nd Annual Healthcare Week, scheduled to run from January 8 to 11, 2024, in San Francisco. Biomica will also be taking part in the Biotech Showcase conference. |
Casterra Appoints New CEO and Expands Team to Drive Growth and InnovationCasterra Ag Ltd., a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN) and an integrated castor cultivation solution company for the bio-based industries (e.g. biofuels, biopolymers), today announced the appointment of Mr. Yoash Zohar as new CEO, as of January 1, 2024, to lead the company's expansion efforts. Considering Casterra's rapid growth and its continued prospects for development, this nomination aims to strengthen its leadership and positioning in the industry. |
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year. |
Lavie Bio Announces a Distribution Agreement with WinField United Canada for its Bio-Inoculant Seed Treatment Yalos™Lavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, today announced a distribution agreement exclusive to independent retail with WinField United Canada for its bio-inoculant seed treatment Yalos™. This partnership aims to support Lavie Bio's 2024 sales growth strategy in Canada, with a focus on key agricultural regions, including Saskatchewa |
Bears are Losing Control Over Evogene (EVGN), Here's Why It's a 'Buy' NowAfter losing some value lately, a hammer chart pattern has been formed for Evogene (EVGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
Lavie Bio Announces Expansion of its Bio-Inoculant Product for Spring Wheat, Yalos™, to Durum and BarleyLavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading ag-biological company committed to elevating food quality, sustainability, and agricultural productivity through microbiome-based innovations, is pleased to announce the expansion of its microbiome-based product for spring wheat, now rebranded as Yalos™ (formerly Thrivus™), to include durum and barley, significantly broadening its potential market reach. This expansion follows very successful field trials conduct |
Evogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call TranscriptEvogene Ltd. (NASDAQ:EVGN) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Third Quarter 2023 Results Conference Call. All participants are present in listen-only mode. Following management’s formal presentation, instructions will be given for the question-and-answer session. [Operator Instructions] As a reminder, this conference […] |
Evogene Reports Third Quarter 2023 Financial ResultsEvogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize the development of life-science-based products utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the third quarter period ended September 30, 2023. |
Lavie Bio Reports Advancement in Bio-Fungicide Program Against Downy Mildew with 2023 Field Trial ResultsLavie Bio Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), and a leading ag-biologicals company that develops microbiome-based, computational-driven bio-stimulant and bio-pesticide novel products, reports significant progress with its bio-fungicide LAV321, discovered and optimized using Lavie Bio's Biology Driven Design (BDD) platform powered by Evogene's MicroBoost AI tech-engine. In 2023 Lavie Bio achieved positive results in a series of field trials conducted across Europe and |
Evogene Schedules Third Quarter 2023 Financial Results Release & Conference Call for November 15, 2023Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that it will release its financial results for the third quarter of 2023, on Wednesday, November 15, 2023. |